vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and Veris Residential, Inc. (VRE). Click either name above to swap in a different company.

Veris Residential, Inc. is the larger business by last-quarter revenue ($70.1M vs $48.0M, roughly 1.5× BICYCLE THERAPEUTICS PLC). Veris Residential, Inc. runs the higher net margin — -20.0% vs -42.0%, a 22.0% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs 3.5%). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 1.9%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Veris Residential, Inc. is an American real estate investment trust headquartered in Jersey City, New Jersey, investing primarily in apartments in New Jersey and Boston.

BCYC vs VRE — Head-to-Head

Bigger by revenue
VRE
VRE
1.5× larger
VRE
$70.1M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1189.8% gap
BCYC
1193.3%
3.5%
VRE
Higher net margin
VRE
VRE
22.0% more per $
VRE
-20.0%
-42.0%
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
1.9%
VRE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCYC
BCYC
VRE
VRE
Revenue
$48.0M
$70.1M
Net Profit
$-20.2M
$-14.0M
Gross Margin
95.9%
Operating Margin
-51.5%
-22.2%
Net Margin
-42.0%
-20.0%
Revenue YoY
1193.3%
3.5%
Net Profit YoY
61.1%
-30.9%
EPS (diluted)
$-0.29
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
VRE
VRE
Q1 26
$70.1M
Q4 25
$48.0M
$71.3M
Q3 25
$11.7M
$73.4M
Q2 25
$2.9M
$75.9M
Q1 25
$10.0M
$67.8M
Q4 24
$3.7M
$68.1M
Q3 24
$2.7M
$68.2M
Q2 24
$9.4M
$67.5M
Net Profit
BCYC
BCYC
VRE
VRE
Q1 26
$-14.0M
Q4 25
$-20.2M
$-203.0K
Q3 25
$-59.1M
$75.2M
Q2 25
$-79.0M
$10.9M
Q1 25
$-60.8M
$-10.7M
Q4 24
$-12.4M
Q3 24
$-50.8M
$-9.7M
Q2 24
$-39.8M
$2.9M
Gross Margin
BCYC
BCYC
VRE
VRE
Q1 26
95.9%
Q4 25
97.2%
Q3 25
96.8%
Q2 25
97.2%
Q1 25
95.9%
Q4 24
97.1%
Q3 24
96.9%
Q2 24
97.3%
Operating Margin
BCYC
BCYC
VRE
VRE
Q1 26
-22.2%
Q4 25
-51.5%
-0.9%
Q3 25
-558.6%
Q2 25
-2965.8%
15.8%
Q1 25
-703.7%
-20.4%
Q4 24
-21.9%
Q3 24
-2385.9%
-16.2%
Q2 24
-498.3%
2.2%
Net Margin
BCYC
BCYC
VRE
VRE
Q1 26
-20.0%
Q4 25
-42.0%
-0.3%
Q3 25
-503.7%
102.4%
Q2 25
-2703.8%
14.4%
Q1 25
-608.9%
-15.8%
Q4 24
-18.3%
Q3 24
-1898.4%
-14.2%
Q2 24
-425.3%
4.3%
EPS (diluted)
BCYC
BCYC
VRE
VRE
Q1 26
$-0.15
Q4 25
$-0.29
$0.00
Q3 25
$-0.85
$0.80
Q2 25
$-1.14
$0.12
Q1 25
$-0.88
$-0.12
Q4 24
$-0.14
Q3 24
$-0.74
$-0.10
Q2 24
$-0.77
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
VRE
VRE
Cash + ST InvestmentsLiquidity on hand
$628.1M
$9.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$610.0M
$1.1B
Total Assets
$717.6M
$2.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
VRE
VRE
Q1 26
$9.4M
Q4 25
$628.1M
$14.1M
Q3 25
$648.3M
$8.8M
Q2 25
$721.5M
$11.4M
Q1 25
$793.0M
$7.6M
Q4 24
$879.5M
$7.3M
Q3 24
$890.9M
$12.8M
Q2 24
$961.4M
$18.4M
Total Debt
BCYC
BCYC
VRE
VRE
Q1 26
Q4 25
$1.4B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
$30.9M
Stockholders' Equity
BCYC
BCYC
VRE
VRE
Q1 26
$1.1B
Q4 25
$610.0M
$1.2B
Q3 25
$618.5M
$1.2B
Q2 25
$668.9M
$1.1B
Q1 25
$740.3M
$1.1B
Q4 24
$793.1M
$1.1B
Q3 24
$831.0M
$1.1B
Q2 24
$873.8M
$1.1B
Total Assets
BCYC
BCYC
VRE
VRE
Q1 26
$2.7B
Q4 25
$717.6M
$2.7B
Q3 25
$764.0M
$2.8B
Q2 25
$832.2M
$3.1B
Q1 25
$883.9M
$3.0B
Q4 24
$956.9M
$3.0B
Q3 24
$996.7M
$3.0B
Q2 24
$1.1B
$3.0B
Debt / Equity
BCYC
BCYC
VRE
VRE
Q1 26
Q4 25
1.18×
Q3 25
Q2 25
Q1 25
Q4 24
1.52×
Q3 24
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
VRE
VRE
Operating Cash FlowLast quarter
$-19.3M
$14.0M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-41.5%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
VRE
VRE
Q1 26
$14.0M
Q4 25
$-19.3M
$76.0M
Q3 25
$-71.2M
$13.5M
Q2 25
$-72.8M
$23.8M
Q1 25
$-86.4M
$13.2M
Q4 24
$-164.7M
$52.3M
Q3 24
$-39.8M
$13.9M
Q2 24
$-44.6M
$10.8M
Free Cash Flow
BCYC
BCYC
VRE
VRE
Q1 26
Q4 25
$-19.9M
Q3 25
$-71.8M
Q2 25
$-73.3M
Q1 25
$-87.0M
Q4 24
$-166.0M
Q3 24
$-40.3M
Q2 24
$-45.0M
FCF Margin
BCYC
BCYC
VRE
VRE
Q1 26
Q4 25
-41.5%
Q3 25
-612.3%
Q2 25
-2509.7%
Q1 25
-871.7%
Q4 24
-4475.7%
Q3 24
-1504.7%
Q2 24
-481.2%
Capex Intensity
BCYC
BCYC
VRE
VRE
Q1 26
Q4 25
1.2%
Q3 25
5.7%
Q2 25
17.1%
Q1 25
6.1%
Q4 24
33.3%
Q3 24
16.3%
Q2 24
4.5%
Cash Conversion
BCYC
BCYC
VRE
VRE
Q1 26
Q4 25
Q3 25
0.18×
Q2 25
2.18×
Q1 25
Q4 24
Q3 24
Q2 24
3.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons